ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Pacific Biosciences of California, Inc." (PACB) Report Updated: Sep 01, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Pacific Biosciences of California, Inc." (PACB)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Life Sciences Tools & Services
Competitors: ICLR, CRL, NEO, ENZ

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Pacific Biosciences of California, Inc."© quotemedia

Company Profile

Pacific Biosciences of California, Inc., a development stage company, develops, manufactures, and markets an integrated platform for genetic analysis. The company engages in developing a technology platform that enables single molecule, real-time (SMRT) for the detection of biological processes. It primarily focuses on the deoxyribonucleic acid sequencing market. The company’s product includes the PacBio RS, a sequencing platform, which consists of an instrument platform that uses its proprietary consumables, such as SMRT Cells and reagent kits. The company’s customers include genome centers, genomics service providers, and agricultural companies, as well as clinical, government, and academic institutions. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Recent News: "Pacific Biosciences of California, Inc."